Medeiros, B C
Fathi, A T
DiNardo, C D
Pollyea, D A
Chan, S M
Swords, R
Article History
Received: 28 June 2016
Revised: 17 August 2016
Accepted: 25 August 2016
First Online: 10 October 2016
Competing interests
: BCM has received research funding from Celgene and Agios and has received remuneration for Advisory Board participation from Celgene and Agios. ATF is a consultant for and receives clinical research funding from Celgene and declares Advisory Board participation for Agios. CDD has received research funding from Novartis, Celgene, Agios and Abbvie/Genentech and participates in Advisory Boards for Celgene and Agios. DAP has received research funding from Celgene and is a consultant for Celgene, Pfizer, Alexion, Ariad and Karyopharm. SMC has received research funding from Celgene, Agios and Abbvie/Genentech. RS declares Advisory Board participation for Novartis.